Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780811 | 0.87 | HDAC1 (0.35) | HDAC1HDAC8DPP4NTRK1CHRM4 | |
| SCHEMBL14688085 | 0.78 | CYP3A4 (0.47) | — | |
| SCHEMBL14688086 | 0.78 | CYP3A4 (0.47) | — | |
| SCHEMBL30136579 | 0.75 | HDAC1 (0.36) | HDAC1HDAC8DPP4CHRM4 | |
| SCHEMBL697736 | 0.75 | KDM4E (0.39) | HDAC1HDAC8DPP4PDPK1 | |
| SCHEMBL30136575 | 0.75 | HDAC1 (0.35) | HDAC1HDAC8DPP4PDPK1 | |
| SCHEMBL749410 | 0.75 | HDAC1 (0.35) | HDAC1HDAC8DPP4PDPK1 | |
| SCHEMBL697735 | 0.75 | KDM4E (0.39) | HDAC1HDAC8DPP4PDPK1 | |
| SCHEMBL749408 | 0.75 | HDAC1 (0.35) | HDAC1HDAC8DPP4PDPK1 | |
| SCHEMBL749409 | 0.75 | HDAC1 (0.35) | HDAC1HDAC8DPP4PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | claimed |
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| EP-2430025-A1 | SITAGLIPTIN SYNTHESIS | Generics [UK] Limited (GB) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | DPP4, DPP7, DPP3 | HDAC1 3285/4885HDAC8 3312/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.